Literature DB >> 19952150

Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.

Jennifer Schultz1, Vijay Joish.   

Abstract

OBJECTIVE: This study determined whether persons with major depressive disorder who switch or augment antidepressant therapy have higher health care costs and productivity losses than those who do not.
METHODS: Data from July 1, 2002, through June 30, 2006, were taken from a national employment-based medical and pharmacy claims database. Participants were required to have filled an antidepressant prescription, be treatment naïve six months before the index prescription, be continuously enrolled in the benefits plan at least six months before and 12 months after the index prescription, and have at least one outpatient-based medical claim for major depressive disorder. Participants were categorized according to whether they switched, augmented, or maintained (that is, neither switched nor augmented) their antidepressant therapy in the 12 months after the index prescription. Productivity losses were defined as days absent from work for medical visits multiplied by average daily wage. Multivariate analyses (generalized linear models) were used to compare costs per person in the year after the index prescription, and univariate analyses (Wilcoxon tests) were used to compare productivity losses per person.
RESULTS: Of the 7,273 individuals who met study criteria, 40.3% switched, 1.5% augmented, and 58.2% maintained the index antidepressant therapy. After the analyses controlled for baseline characteristics, mean total and depression-related health care costs, respectively, in the year after the index prescription were significantly greater for switchers ($9,288 and $1,388 per person) and for augmenters ($9,350 and $1,027) than for maintainers ($6,151 and $723). Mean total and depression-related productivity losses, respectively, were significantly greater for switchers ($2,081 and $680) and augmenters ($2,010 and $587) than for maintainers ($1,424 and $437).
CONCLUSIONS: Persons with major depressive disorder who switched or augmented antidepressant therapy within 12 months of treatment initiation had higher resource costs and productivity losses than those who did not.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952150     DOI: 10.1176/ps.2009.60.12.1604

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  9 in total

1.  Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Authors:  Christian A Webb; Madhukar H Trivedi; Zachary D Cohen; Daniel G Dillon; Jay C Fournier; Franziska Goer; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Ramin Parsey; Phil Adams; Joseph M Trombello; Crystal Cooper; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Quentin Huys; Gerard Bruder; Benji T Kurian; Manish Jha; Robert J DeRubeis; Diego A Pizzagalli
Journal:  Psychol Med       Date:  2018-07-02       Impact factor: 7.723

2.  Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder.

Authors:  Drishti Shah; Wanhong Zheng; Lindsay Allen; Wenhui Wei; Traci LeMasters; Suresh Madhavan; Usha Sambamoorthi
Journal:  Curr Med Res Opin       Date:  2021-03-24       Impact factor: 2.580

3.  Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.

Authors:  Drishti Shah; Lindsay Allen; Wanhong Zheng; Suresh S Madhavan; Wenhui Wei; Traci J LeMasters; Usha Sambamoorthi
Journal:  Pharmacoeconomics       Date:  2021-04-27       Impact factor: 4.558

4.  Age and Gender Differences in Trends and Impact of Depression on Quality of Life in the United States, 2008 to 2016.

Authors:  Ronald Anguzu; Sneha Nagavally; Aprill Z Dawson; Rebekah J Walker; Leonard E Egede
Journal:  Womens Health Issues       Date:  2021-03-30

5.  Factors associated with switching and combination use of antidepressants in young Swedish adults.

Authors:  K Andersson Sundell; M G Petzold; S M Wallerstedt
Journal:  Int J Clin Pract       Date:  2013-10-09       Impact factor: 2.503

6.  Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.

Authors:  Shien Guo; Denis Getsios; Luis Hernandez; Kelly Cho; Elizabeth Lawler; Arman Altincatal; Stephan Lanes; Michael Blankenburg
Journal:  Int J Alzheimers Dis       Date:  2012-12-26

7.  What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.

Authors:  Susan Ball; Peter Classi; Ellen B Dennehy
Journal:  Ann Gen Psychiatry       Date:  2014-03-19       Impact factor: 3.455

8.  Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study.

Authors:  Josep Maria Haro; François-Xavier Lamy; Bengt Jönsson; Martin Knapp; Mélanie Brignone; Hugo Caillou; Ylana Chalem; Lene Hammer-Helmich; Benoît Rive; Delphine Saragoussi
Journal:  BMC Psychiatry       Date:  2018-03-27       Impact factor: 3.630

9.  Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case-Control Cohort Analysis.

Authors:  Aki Shiozawa; Sari Hopson; Rupali Fuldeore; Matthias Stoelzel; Daniel Ng; John Hairston
Journal:  Adv Ther       Date:  2020-09-10       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.